Mild Traumatic
Brain Injury

Our Focus

Mild Traumatic Brain Injury (mTBI) is an increasingly prevalent disease condition affecting millions of people globally on an acute and chronic basis. Mild Traumatic Brain Injury is now classified as a silent epidemic because patients suffering from this disease have problems that are not “visible” on the surface.

At the current time there is no approved therapeutic drug available on the market, and the prognosis for recovery of patients diagnosed with mTBI can be poor. Sustaining mTBI can put you at a higher risk for developing other neurodegenerative diseases such as dementia and Alzheimer’s Disease

What is mTBI?

Mild Traumatic Brain Injury is a traumatically induced physiological disruption to brain function and is manifested by at least one of the following:

A period of loss of consciousness
Any loss of memory for events immediately before or after the accident
Any alteration in mental state at the time of the accident (e.g., feeling dazed, disoriented, or confused)

It is distinguished from moderate and severe TBI which can typically include a loss of consciousness of greater than 30 minutes, post traumatic amnesia of greater than 24 hours, and Glasgow Coma scale rating below 12.

mTBI or concussions are caused by:

A bump, blow, or jolt to the head, or
By a hit to the body that causes the head and brain to move quickly back and forth

Over 80% of all cases of TBI are mTBI

Current Treatments

There is little that can be done to reverse initial brain damage caused by trauma. However, on-going research suggests that although a person can recover fully on their own from an incident of mTBI, (that is all the symptoms associated with mTBI have disappeared), they are still at a higher risk of developing other neurological diseases later in life such as dementia and Alzheimer’s Disease. Moreover, even in those who do have a spontaneous recovery the time course can be slow having a dramatic impact on the quality of life for many weeks or months.

ECP Pharma's Research & Treatment Method

ECP Pharma’s unique drug therapy involving cannabinoids and psychedelics will be used to promote a quick recovery and overcome the long-term consequences often seen with mTBI.

Following a proof-of-concept study in rats showing promising results, ECP Pharma is moving forward in developing this drug for first in human trials to study the safety and effectiveness profile of this new drug dosing regimen.